Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

NCT05841030 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with anhedonia with inadequate response to their current antidepressant treatments and treated according to the standard of care treatment.

Conditions Studied

Interventions

  • OTHER No Intervention

Study Locations (20)

Florida

  • Flagler Hospital and Florida Center for TMS — Saint Augustine
  • Center for Revitalizing Psychiatry — Sarasota
  • Interventional Psychiatry of Tampa Bay — Tampa

Illinois

  • University of Chicago — Chicago
  • Loyola University Medical Center — Maywood
  • Baber Research Group — Naperville

Alabama

  • University of Alabama at Birmingham — Birmingham
  • University of Alabama at Birmingham — Homewood

Georgia

  • Atlanta Behavioral Research, LLC — Atlanta
  • Psych Atlanta, P.C. — Marietta

Massachusetts

  • Lumin Health — Newton
  • Univeristy of Massachusetts — Worcester

Other

  • Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales — Buenos Aires
  • Hospital Italiano de Buenos Aires — Buenos Aires

California

  • ATP Clinical Research — California City

Connecticut

  • University of Connecticut Health Center — Farmington

Trial Details

FieldValue
Enrollment Target 545 participants
Start Date 2023-04-28
Est. Completion 2026-03-13

Sponsor

Janssen Research & Development

442 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05841030

The ClinicalTrials.gov registry entry for NCT05841030 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 545 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 442 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 1 intervention — of which No Intervention is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05841030 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Florida, Illinois, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05841030 about?

NCT05841030 is a clinical study titled "A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)". The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with anhedonia with inadequate response to their current antidepressant treatmen...

What is the current status of trial NCT05841030?

This trial is currently active not recruiting. The enrollment target is 545 participants. The study started on 2023-04-28. Estimated completion is 2026-03-13.

What conditions does trial NCT05841030 study?

This clinical trial studies the following conditions: Depressive Disorder, Major. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05841030?

The interventions under investigation include: No Intervention (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05841030?

This trial is sponsored by Janssen Research & Development, which has 442 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05841030 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial